Effect of Aspirin on Disability-free Survival in the Healthy Elderly
Source: View publication →
In healthy community-dwelling older adults, daily low-dose aspirin did not prolong disability-free survival but significantly increased the risk of major hemorrhage compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ASPREE trial fundamentally shifted clinical guidelines regarding the routine use of aspirin for primary prevention in older adults. By demonstrating that the bleeding risks of low-dose aspirin outweigh any theoretical benefits in preventing cardiovascular events or extending healthy lifespan, it established that aspirin should generally not be initiated for primary prevention in patients aged 70 and older.
Historical Context
For decades, aspirin was widely prescribed as a primary prevention tool to prevent heart attacks and strokes, largely based on extrapolation from robust secondary prevention data and earlier trials in middle-aged populations (e.g., the Physicians' Health Study). However, background rates of cardiovascular disease have declined over time due to lower smoking rates and the widespread use of statins and antihypertensives. In 2018, the simultaneous publication of the ASPREE, ASCEND (in diabetics), and ARRIVE (in moderate-risk patients) trials decisively proved that for modern primary prevention populations, the absolute risk of major bleeding associated with aspirin generally nullifies or exceeds its modest cardiovascular benefits.
Guided Discussion
High-yield insights from every perspective
Through what mechanism does aspirin increase the risk of major hemorrhage, and why are older adults particularly susceptible to this adverse effect?
Key Response
Aspirin irreversibly inhibits COX-1, preventing thromboxane A2 synthesis and impairing platelet aggregation for the lifespan of the platelet. Older adults have age-related vascular fragility, increased prevalence of cerebral amyloid angiopathy, and reduced gastrointestinal mucosal integrity, making them significantly more vulnerable to severe bleeding complications from impaired hemostasis.
How should the results of the ASPREE trial change your approach to a 72-year-old patient who presents for an annual wellness visit and is currently taking daily low-dose aspirin 'for their heart' without any history of cardiovascular disease?
Key Response
The resident must recognize this as primary prevention in an older adult. ASPREE showed no disability-free survival benefit and significantly increased bleeding risk. Management involves discussing the risks of continued therapy and safely deprescribing aspirin, recognizing that historical practices of universal aspirin use for primary prevention are no longer supported by current evidence.
ASPREE reported an unexpected increase in all-cause mortality in the aspirin group, primarily attributed to cancer-related deaths. How does this finding contrast with prior evidence regarding aspirin and cancer, and how should a specialist interpret this paradox?
Key Response
Previous studies suggested aspirin has a delayed protective effect against colorectal cancer incidence and mortality. The ASPREE finding of increased cancer mortality was unexpected. Fellows should understand that while aspirin might prevent early neoplastic transformation in middle age, initiating it in older age could potentially promote the progression, metastasis, or bleeding complications of established microscopic tumors, though it may also represent a statistical chance finding.
As an attending physician, how do you navigate the shared decision-making process with a long-term patient who has been on primary prevention aspirin for 20 years, given that ASPREE specifically focused on initiating aspirin rather than continuing it?
Key Response
ASPREE studied the initiation of aspirin in adults over 70. Discontinuing aspirin in someone who has tolerated it for decades without bleeding involves different risk-benefit calculations. Attendings must teach trainees to differentiate between avoiding initiation versus deprescribing in chronic users, emphasizing personalized shared decision-making that weighs the cumulative bleeding risk of aging against the psychological and unknown physiological risks of withdrawal.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ASPREE trial used a composite primary endpoint of 'disability-free survival' encompassing death, dementia, or persistent physical disability. What are the methodological advantages and potential statistical pitfalls of using this specific composite endpoint in a geriatric primary prevention trial?
Key Response
Advantages include capturing the true net clinical benefit relevant to older adults (quality of life and independence) rather than isolated surrogate cardiovascular events, and increasing statistical power. Pitfalls include the assumption that the components are of equal weight to the patient, and that the intervention might have opposing effects on different components (e.g., reducing vascular dementia but increasing hemorrhagic stroke death), muddying the interpretation of the overall treatment effect.
If reviewing the ASPREE manuscript, how would you critically evaluate the generalizability of the findings given the trial's enrollment criteria, specifically the requirement for participants to be entirely free of cardiovascular disease, dementia, and physical disability at age 70?
Key Response
A seasoned reviewer would flag the 'healthy volunteer effect'. By requiring individuals to reach age 70 without any of these conditions, the trial selected for a highly resilient biological subset of the population. The editorial significance is whether these findings apply to the typical 70-year-old seen in clinical practice, who often has mild cognitive or physical impairments and multiple comorbidities, potentially altering the baseline risk-to-benefit ratio.
Based on the ASPREE findings, how should cardiovascular prevention guidelines be updated regarding the age cutoffs and strength of recommendation for routine aspirin use in primary prevention?
Key Response
Following ASPREE (alongside ARRIVE and ASCEND), guidelines such as the 2019 ACC/AHA guidelines were updated to state that low-dose aspirin should not be administered on a routine basis for primary prevention of ASCVD among adults over 70 years of age (Class III recommendation: Harm). The committee must justify shifting from older, more permissive guidelines to a strong recommendation against use, citing definitive RCT evidence demonstrating that bleeding harm definitively outweighs ischemic benefit in this demographic.
Clinical Landscape
Noteworthy Related Trials
Women's Health Study (WHS)
Tested
Aspirin 100 mg every other day
Population
Initially healthy women aged 45 years or older
Comparator
Placebo
Endpoint
First major cardiovascular event (nonfatal MI, nonfatal stroke, or CV death)
ASCEND Trial
Tested
Aspirin 100 mg daily
Population
Adults with diabetes mellitus without evident cardiovascular disease
Comparator
Placebo
Endpoint
First serious vascular event (MI, stroke, TIA, or CV death)
ARRIVE Trial
Tested
Aspirin 100 mg enteric-coated daily
Population
Adults at moderate estimated risk of a first cardiovascular event
Comparator
Placebo
Endpoint
Composite of CV death, MI, unstable angina, stroke, or TIA
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis